| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/18/2006 | EP1615951A2 Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections |
| 01/18/2006 | EP1615944A2 Antiandrogens with marginal agonist activity and methods of use |
| 01/18/2006 | EP1615932A2 Podophhyllotoxin derivatives as igf-1r inhibitors |
| 01/18/2006 | EP1615930A2 Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists |
| 01/18/2006 | EP1615922A1 Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
| 01/18/2006 | EP1615921A2 Pyrido 2,3-d pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| 01/18/2006 | EP1615920A1 3-benzhydrylidene-8-aza-bicyclo [3.2.1] octane derivatives with opioid receptor activity |
| 01/18/2006 | EP1615916A1 Antimicrobial 3.1.0 bicyclohexylphenyl-oxazolidinone derivatives and analogues |
| 01/18/2006 | EP1615914A2 Cgrp receptor antagonists |
| 01/18/2006 | EP1615910A1 Processes for the preparation of n-((((pyridinyloxy)-phenylamino)quinazolinyl)-allyl)acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates |
| 01/18/2006 | EP1615905A2 Benzopyran compounds useful for treating inflammatory conditions |
| 01/18/2006 | EP1615897A2 Pyrimidinone compounds as calcilytics |
| 01/18/2006 | EP1615894A2 3-azabicyclo 3.2.1 octane derivatives |
| 01/18/2006 | EP1615889A2 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| 01/18/2006 | EP1615887A1 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| 01/18/2006 | EP1615886A1 [c]-fused bicyclic proline derivatives and their use for treating arthritic conditions |
| 01/18/2006 | EP1615884A1 Process for the preparation of amorphous calcium salt of atorvastatin |
| 01/18/2006 | EP1615880A2 Preparation and purification of synthetic capsaicin |
| 01/18/2006 | EP1615879A1 Process for the production of 9-cis retinoic acid |
| 01/18/2006 | EP1615878A2 Compounds, compositions and methods |
| 01/18/2006 | EP1615699A2 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
| 01/18/2006 | EP1615698A2 New amide derivatives and pharmaceutical use thereof |
| 01/18/2006 | EP1615697A2 New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
| 01/18/2006 | EP1615669A2 Peg-wortmannin conjugates |
| 01/18/2006 | EP1615668A1 A medicament for the two-step perioperative therapy of solid tumours by radioimmunotherapy |
| 01/18/2006 | EP1615663A1 Agent for treating leishmania infections |
| 01/18/2006 | EP1615658A1 Inhibition of tumor cell proliferation by foxm1b inhibitors |
| 01/18/2006 | EP1615650A1 Phosphate derivatives of pharmaceutical products |
| 01/18/2006 | EP1615649A1 Parenteral formulation of mycophenolic acid, a salt or prodrug thereof |
| 01/18/2006 | EP1615648A2 High drug load mesalazine sachet |
| 01/18/2006 | EP1615647A2 Pharmaceutical use of fused 1,2,4-triazoles |
| 01/18/2006 | EP1615646A1 Pharmaceutical formulations containing methylnaltrexone |
| 01/18/2006 | EP1615645A1 A crystalline form iii of anhydrous moxifloxacin hydrochloride and a process for preparation thereof |
| 01/18/2006 | EP1615644A1 Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists with antidepressant and anxiolytic activity |
| 01/18/2006 | EP1615643A1 4-phenyl-piperidine compounds and their use as modulators of opioid receptors |
| 01/18/2006 | EP1615642A1 Combination of paroxetine and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)- (2s-phenyl-piperidin-3s-yl)-amine for treatment of depression and/or anxiety |
| 01/18/2006 | EP1615641A1 Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo 1,2-a -pyrazin-2-yl)-piperidine-1-carboxylic acid 1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl -methylamide for treatment of depression/anxiety |
| 01/18/2006 | EP1615640A2 Antineoplastic combinations |
| 01/18/2006 | EP1615639A2 Targeted bone marrow protection agents |
| 01/18/2006 | EP1615638A1 Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy |
| 01/18/2006 | EP1615637A1 Pharmaceutical use of substituted 1,2,4-triazoles |
| 01/18/2006 | EP1615635A1 Pharmaceutical combination comprising eletriptan and sodium bicarbonate |
| 01/18/2006 | EP1615634A1 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| 01/18/2006 | EP1615633A2 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 01/18/2006 | EP1615632A1 Floating oral formulations for controlled release of betaine |
| 01/18/2006 | EP1615631A2 Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases |
| 01/18/2006 | EP1615630A1 Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol |
| 01/18/2006 | EP1615629A1 Peptide deformylase inhibitors |
| 01/18/2006 | EP1615627A1 Pharmaceutical composition containing levodopa and carbidopa |
| 01/18/2006 | EP1615624A2 Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient |
| 01/18/2006 | EP1615623A2 Abuse-resistant oral dosage forms and method of use thereof |
| 01/18/2006 | EP1615622A2 Once daily formulations of tetracyclines |
| 01/18/2006 | EP1615621A2 Compositions for delivery of drug combinations |
| 01/18/2006 | EP1615619A2 Sachet for a pharmaceutical composition |
| 01/18/2006 | EP1615615A2 Pharmaceutical products |
| 01/18/2006 | EP1615613A2 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors |
| 01/18/2006 | EP1615611A2 iRNA CONJUGATES |
| 01/18/2006 | EP1615552A2 Sapphyrins and uses thereof |
| 01/18/2006 | EP1501505B1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h- 1,2,4 -triazole for the treatment of autoimmune diseases |
| 01/18/2006 | EP1487427A4 Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline |
| 01/18/2006 | EP1470138B1 Mmp inhibitors |
| 01/18/2006 | EP1435951B1 Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity |
| 01/18/2006 | EP1432683B9 Novel crystalline polymorphic forms of lercanidipine hydrochloride and processes for their preparation |
| 01/18/2006 | EP1430138B1 Process for producing pravastatin sodium salt using streptomyces flavidovirens dsm 14455 |
| 01/18/2006 | EP1412338B1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 01/18/2006 | EP1404672B1 Tyrosine kinase inhibitors |
| 01/18/2006 | EP1404347B1 4'-substituded nucleosides for the treatment of diseases mediated by the hepatitis c virus |
| 01/18/2006 | EP1392309A4 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| 01/18/2006 | EP1381601B1 Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same |
| 01/18/2006 | EP1363612A4 Peptide deformylase inhibitors |
| 01/18/2006 | EP1318761A4 Concurrent tooth repositioning and substance delivery |
| 01/18/2006 | EP1292590B1 Admantane derivatives |
| 01/18/2006 | EP1286663B1 Encapsulating a toxic core within a non-toxic region in an oral dosage form |
| 01/18/2006 | EP1278851B1 Humanised antibodies to the epidermal growth factor receptor |
| 01/18/2006 | EP1268096B1 Extrusion die |
| 01/18/2006 | EP1255733B1 Farnesyl transferase inhibitors |
| 01/18/2006 | EP1226819B1 Inhibitor for 20-hete-yielding enzyme |
| 01/18/2006 | EP1220852B1 Substituted diazepans |
| 01/18/2006 | EP1219595B1 O-anisamide derivatives |
| 01/18/2006 | EP1214064A4 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 01/18/2006 | EP1213965B1 Thrombopoietin mimetics |
| 01/18/2006 | EP1212335B1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1- 4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| 01/18/2006 | EP1210327B1 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 01/18/2006 | EP1210085B1 Pharmaceutical solutions of levosimendan |
| 01/18/2006 | EP1207161B1 Novel isoindole derivatives |
| 01/18/2006 | EP1200320B9 Valve with a two-component seal |
| 01/18/2006 | EP1194410B1 Benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| 01/18/2006 | EP1169475B1 Diagnosis of a person's risk for developing diabetic retinopathy |
| 01/18/2006 | EP1097162B1 Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages |
| 01/18/2006 | EP1028708A4 Topical compositions for prostaglandin e 1? delivery |
| 01/18/2006 | EP1018548B1 Cellular immunogenicity potentiating composition containing alpha-glycosylceramide |
| 01/18/2006 | EP0998274B1 Microdose therapy of vascular conditions by no donors |
| 01/18/2006 | EP0973727B8 Activated iododerivatives for the treatment of cancer and aids |
| 01/18/2006 | EP0954308B1 Therapeutic treatment for cardiovascular diseases |
| 01/18/2006 | EP0882129B1 Recombinant expression of s-layer proteins |
| 01/18/2006 | EP0866697A4 Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same |
| 01/18/2006 | EP0835120B2 Use of an essential oil comprising thymol and carvacrol for the manufacture of a pharmaceutical composition for the treatment or prvention of coccidiosis in poultry |
| 01/18/2006 | EP0828492B1 Medicaments for preventing intervention-associated stenosis following non-bypass, invasive interventions |
| 01/18/2006 | EP0819004A4 Pharmaceutical composition containing proton pump inhibitors |
| 01/18/2006 | EP0782630B1 Polycystic kidney disease gene |